173 related articles for article (PubMed ID: 35309346)
21. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
22. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
Ringdén O; Pavletic SZ; Anasetti C; Barrett AJ; Wang T; Wang D; Antin JH; Di Bartolomeo P; Bolwell BJ; Bredeson C; Cairo MS; Gale RP; Gupta V; Hahn T; Hale GA; Halter J; Jagasia M; Litzow MR; Locatelli F; Marks DI; McCarthy PL; Cowan MJ; Petersdorf EW; Russell JA; Schiller GJ; Schouten H; Spellman S; Verdonck LF; Wingard JR; Horowitz MM; Arora M
Blood; 2009 Mar; 113(13):3110-8. PubMed ID: 19059878
[TBL] [Abstract][Full Text] [Related]
23. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
24. [HLA-10/10 matched unrelated donor versus sibling donor hematopoietic stem cell transplantation for adult acute myeloid leukemia].
Yao JF; Zhang GX; Shen YY; Zhang RL; He Y; Wei JL; Jiang EL; Yang DL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):460-466. PubMed ID: 31340617
[No Abstract] [Full Text] [Related]
25. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
[TBL] [Abstract][Full Text] [Related]
26. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
27. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
[TBL] [Abstract][Full Text] [Related]
28. Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
Kordelas L; Schwich E; Lindemann M; Heinemann FM; Buttkereit U; Horn PA; Beelen DW; Rebmann V
Front Immunol; 2019; 10():3027. PubMed ID: 31998310
[TBL] [Abstract][Full Text] [Related]
29. HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies.
Battiwalla M; Ellis K; Li P; Pavletic SZ; Akpek G; Hematti P; Klumpp TR; Maziarz RT; Savani BN; Aljurf MD; Cairo MS; Drobyski WR; George B; Hahn T; Khera N; Litzow MR; Loren AW; Saber W; Arora M; Urbano-Ispizua A; Cutler C; Flowers ME; Spellman SR
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1302-8. PubMed ID: 22414493
[TBL] [Abstract][Full Text] [Related]
30. Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience.
Delia M; Pastore D; Mestice A; Carluccio P; Perrone T; Gaudio F; Ricco A; Sgherza N; Albano F; Specchia G
Biol Blood Marrow Transplant; 2013 Mar; 19(3):495-9. PubMed ID: 23200706
[TBL] [Abstract][Full Text] [Related]
31. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
[TBL] [Abstract][Full Text] [Related]
32. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
[TBL] [Abstract][Full Text] [Related]
33. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Soiffer RJ; Kim HT; McGuirk J; Horwitz ME; Johnston L; Patnaik MM; Rybka W; Artz A; Porter DL; Shea TC; Boyer MW; Maziarz RT; Shaughnessy PJ; Gergis U; Safah H; Reshef R; DiPersio JF; Stiff PJ; Vusirikala M; Szer J; Holter J; Levine JD; Martin PJ; Pidala JA; Lewis ID; Ho VT; Alyea EP; Ritz J; Glavin F; Westervelt P; Jagasia MH; Chen YB
J Clin Oncol; 2017 Dec; 35(36):4003-4011. PubMed ID: 29040031
[TBL] [Abstract][Full Text] [Related]
34. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.
Valcárcel D; Sierra J; Wang T; Kan F; Gupta V; Hale GA; Marks DI; McCarthy PL; Oudshoorn M; Petersdorf EW; Ringdén O; Setterholm M; Spellman SR; Waller EK; Gajewski JL; Marino SR; Senitzer D; Lee SJ
Biol Blood Marrow Transplant; 2011 May; 17(5):640-8. PubMed ID: 20674756
[TBL] [Abstract][Full Text] [Related]
35. The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study.
Nagler A; Dholaria B; Labopin M; Bruno B; Rambaldi A; Pioltelli P; La Nasa G; Socié G; Mielke S; Ruggeri M; Saccardi R; Franke GN; Finke J; Savani BN; Ruggeri A; Mohty M
Bone Marrow Transplant; 2021 Jan; 56(1):20-29. PubMed ID: 32561816
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
Rashidi A; Hamadani M; Zhang MJ; Wang HL; Abdel-Azim H; Aljurf M; Assal A; Bajel A; Bashey A; Battiwalla M; Beitinjaneh AM; Bejanyan N; Bhatt VR; Bolaños-Meade J; Byrne M; Cahn JY; Cairo M; Ciurea S; Copelan E; Cutler C; Daly A; Diaz MA; Farhadfar N; Gale RP; Ganguly S; Grunwald MR; Hahn T; Hashmi S; Hildebrandt GC; Holland HK; Hossain N; Kanakry CG; Kharfan-Dabaja MA; Khera N; Koc Y; Lazarus HM; Lee JW; Maertens J; Martino R; McGuirk J; Munker R; Murthy HS; Nakamura R; Nathan S; Nishihori T; Palmisiano N; Patel S; Pidala J; Olin R; Olsson RF; Oran B; Ringden O; Rizzieri D; Rowe J; Savoie ML; Schultz KR; Seo S; Shaffer BC; Singh A; Solh M; Stockerl-Goldstein K; Verdonck LF; Wagner J; Waller EK; De Lima M; Sandmaier BM; Litzow M; Weisdorf D; Romee R; Saber W
Blood Adv; 2019 Jun; 3(12):1826-1836. PubMed ID: 31201170
[TBL] [Abstract][Full Text] [Related]
37. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
38. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
40. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission.
Lee YJ; Baek DW; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Kim HJ; Ham JY; Suh JS; Sohn SK; Moon JH
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e529-e535. PubMed ID: 30268640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
